With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been difficult to track and understand the current IO agents in clinical development and the clinical trials testing these agents. The Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis based on information collected from numerous trusted and publicly available sources.
We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication. We also present the following interactive dashboards of this landscape of immuno-oncology drug development that explore the field:
A comparison of global IO pipelines in 2017 and 2019. 3,876 immuno-oncology agents in six main classes were identified in September 2019, an increase of 91% since 2017. More details can be found in the Nature Reviews Drug Discovery article
Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets.
We have several landscape publications:
- Cancer cell therapies: The clinical trial landscape, Nature Reviews Drug Discovery, May 2020
- Impact of COVID-19 on oncology clinical trials, Nature Reviews Drug Discovery, May 2020
- Trends in clinical development for PD-1/PD-L1 inhibitors, Nature Reviews Drug Discovery, November 2019
- Immuno-Oncology Drug Development Goes Global, Nature Reviews Drug Discovery, September 2019
- The global pipeline of cell therapies for cancer, Nature Reviews Drug Discovery, May 2019
- The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors, Nature Reviews Drug Discovery, November 2018
- Trends in the global immuno-oncology landscape, Nature Reviews Drug Discovery, October 2018
- The global landscape of cancer cell therapy, Nature Reviews Drug Discovery, May 2018
- Comprehensive analysis of the clinical immuno-oncology landscape, Annals of Oncology, December 2017
Additionally, data from our Immuno-Oncology Landscape has been featured in a review of IO combination trials in breast cancer:
Explore other landscapes of immuno-oncology drug development:
Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.
Subscribe to our email newsletter to receive the latest updates on our landscape analyses.